Recent Quotes (30 days)

You have no recent quotes
chg | %

Covalon Technologies Ltd  

(Public, CVE:COV)   Watch this stock  
Find more results for COV
-0.04 (-3.45%)
May 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.12 - 1.18
52 week 1.04 - 2.98
Open 1.18
Vol / Avg. 8,060.00/6,581.00
Mkt cap 10.42M
P/E     -
Div/yield     -
EPS -0.03
Shares 9.31M
Beta -1.11
Inst. own     -
Feb 27, 2015
Q1 2015 Covalon Technologies Ltd Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -17.19% 26.51%
Operating margin -15.00% 26.96%
EBITD margin - 30.23%
Return on average assets -11.54% 35.24%
Return on average equity -16.97% 56.69%
CDP Score - -


405 Britannia Rd E Suite 106
+1-905-5688400 (Phone)
+1-905-5685200 (Fax)

Website links


Covalon Technologies Ltd. (Covalon) is a Canada-based pharmaceutical company. The Company is engaged in the business of developing, licensing and selling medical technologies. The Company operates in two segments: Advanced Wound Care and Specialized Medical Device Coatings. Its offices and laboratories are located in Mississauga, Ontario, Canada. Covalon sells its technologies to medical companies and distributors. Covalon’s antimicrobial technologies can be used for applications in areas, such as medical device coatings, wound care products, polymer mixes for extrusion, skin sanitizers, surface sanitizers, cosmetics, consumer products, veterinary applications, and others. Its products include ColActive, ColActive Ag, ColActive Plus, ColActive Plus Ag and CovaClear Ag. The Company’s wholly owned subsidiaries include Covalon Technologies Inc. and COV Healthcare Innovations Corp.

Officers and directors

Abe Schwartz Chairman of the Board
Brian E. Pedlar President, Chief Executive Officer, Interim Chief Financial Officer, Director
Age: 41
Valerio DiTizio Chief Scientific Officer
Paul Weber Vice President - Business Development
Ian Brindle Director
Elinor Caplan Director
Martin C. Bernholtz Independent Director
Joseph Cordiano Independent Director
Jeffrey A. Mandel Independent Director